<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11432">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690806</url>
  </required_header>
  <id_info>
    <org_study_id>OTO: OTO12-0447R</org_study_id>
    <nct_id>NCT01690806</nct_id>
  </id_info>
  <brief_title>Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy</brief_title>
  <official_title>Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Aquila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Aquila</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important
      complications of thyroid surgery. The duration of convalescence, after non complicated
      thyroid operation, may depend on several factors of which pain and fatigue are the most
      important. Nausea and vomiting occur mainly on the day of operation. Glucocorticoids are
      well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects.
      The investigators therefore undertook the present study to investigate whether preoperative
      dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">328</enrollment>
  <condition>Benign Neoplasm of Thyroid Gland</condition>
  <condition>Malignant Neoplasm of Thyroid</condition>
  <arm_group>
    <arm_group_label>dexamethasone</arm_group_label>
    <description>Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp &amp; Dohme) intravenously 90 min before skin incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>Patients who receive saline placebo intravenously 90 min before skin incision</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients undergoing thyroid surgery for benign and malignant thyroidal disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing thyroid surgery

        Exclusion Criteria:

          -  ASA physical class III or IV

          -  age &gt; 75 years

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuela M CECILIA, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi dell'Aquila</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ospedale San Salvatore-Reparto di Chirurgia Generale Universitaria</name>
      <address>
        <city>L'Aquila</city>
        <state>AQ</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>September 25, 2012</lastchanged_date>
  <firstreceived_date>September 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Aquila</investigator_affiliation>
    <investigator_full_name>CECILIA Emanuela Marina</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Vocal Cord Paralysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
